MOLN
Price
$4.04
Change
+$0.10 (+2.54%)
Updated
May 23 closing price
Capitalization
149.92M
93 days until earnings call
SNSE
Price
$0.30
Change
-$0.00 (-0.00%)
Updated
May 23 closing price
Capitalization
7.45M
68 days until earnings call
Interact to see
Advertisement

MOLN vs SNSE

Header iconMOLN vs SNSE Comparison
Open Charts MOLN vs SNSEBanner chart's image
Molecular Partners AG
Price$4.04
Change+$0.10 (+2.54%)
Volume$10.09K
Capitalization149.92M
Sensei Biotherapeutics
Price$0.30
Change-$0.00 (-0.00%)
Volume$77.54K
Capitalization7.45M
MOLN vs SNSE Comparison Chart
Loading...
SNSE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MOLN vs. SNSE commentary
May 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MOLN is a Hold and SNSE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 24, 2025
Stock price -- (MOLN: $4.04 vs. SNSE: $0.30)
Brand notoriety: MOLN and SNSE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MOLN: 76% vs. SNSE: 2%
Market capitalization -- MOLN: $149.92M vs. SNSE: $7.45M
MOLN [@Biotechnology] is valued at $149.92M. SNSE’s [@Biotechnology] market capitalization is $7.45M. The market cap for tickers in the [@Biotechnology] industry ranges from $298.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MOLN’s FA Score shows that 0 FA rating(s) are green whileSNSE’s FA Score has 1 green FA rating(s).

  • MOLN’s FA Score: 0 green, 5 red.
  • SNSE’s FA Score: 1 green, 4 red.
According to our system of comparison, MOLN is a better buy in the long-term than SNSE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SNSE’s TA Score shows that 3 TA indicator(s) are bullish.

  • SNSE’s TA Score: 3 bullish, 5 bearish.

Price Growth

MOLN (@Biotechnology) experienced а +5.21% price change this week, while SNSE (@Biotechnology) price change was -14.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.22%. For the same industry, the average monthly price growth was +3.23%, and the average quarterly price growth was -2.73%.

Reported Earning Dates

MOLN is expected to report earnings on Aug 25, 2025.

SNSE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MOLN($150M) has a higher market cap than SNSE($7.45M). MOLN YTD gains are higher at: -14.912 vs. SNSE (-39.706). SNSE has higher annual earnings (EBITDA): -28.38M vs. MOLN (-51.65M). MOLN has more cash in the bank: 149M vs. SNSE (47M). MOLN has less debt than SNSE: MOLN (2.44M) vs SNSE (4.47M). MOLN has higher revenues than SNSE: MOLN (4.97M) vs SNSE (0).
MOLNSNSEMOLN / SNSE
Capitalization150M7.45M2,014%
EBITDA-51.65M-28.38M182%
Gain YTD-14.912-39.70638%
P/E RatioN/AN/A-
Revenue4.97M0-
Total Cash149M47M317%
Total Debt2.44M4.47M55%
TECHNICAL ANALYSIS
Technical Analysis
SNSE
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 30 days ago
74%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
SNSE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYENX208.93N/A
N/A
Rydex Energy A
FZADX24.11N/A
N/A
Fidelity Advisor Dividend Growth Z
TIEHX15.38N/A
N/A
Nuveen International Eq I
POIRX16.11N/A
N/A
Polen International Growth Investor
HFECX52.16-0.12
-0.23%
Janus Henderson European Focus C